Table 1.

Characteristics and outcome of lung transplant recipients receiving VRC^d

Patient no.	Age (yr)/sex	Type of transplant	Underlying disease	Timing of bronchoscopy posttransplant (days)	VRC dose regimen (mg b.i.d.)	Timing of sampling after last dose (h)	Treatment duration of VRC prior to BAL (mo)	Plasma (μg/ml)	ELF (μg/ml)	ELF/plasma ratioe	Outcome	Comments
1	53/M	Singlea	IPF	54	200	13.2	1.0	1.67	42.3	25.2	Successb
2	57/M	Double	IPF	197	200	14.1	3.5	3.18	37.9	11.9	Failure	Persistent Paecilomyces variotiic colonization
3	63/F	Double	COPD	14	200	13.0	2.3	0.15	1.56	10.4	Failure	Breakthrough Aspergillus fumigatus colonization
4	49/F	Double	Sarcoidosis	3,285	200	11.8	12	0.57	5.75	10.0	Successb
5	60/F	Double	COPD	227	150	14.0	7.5	3.87	59.5	15.4	Failure	Persistent yeast colonization
6	41/F	Double	Bronchiectasis	2,920	200	25.8	36	0.12	NA	NA	Failure	Persistent Scedosporium prolificans colonization
7	55/F	Singlea	IPF	120	200	16.0	0.75	0.67	2.98	4.5	Successb
8	46/F	Double	IPF	180	150	16.0	2.5	0.09	NA	NA	Successb
9	61/F	Double	COPD	99	200	13.0	0.38	3.99	NA	NA	Successb
10	38/M	Double	ILD and PAH	95	200	13.8	1.25	0.48	2.92	6.1	Successb
11	58/F	Double	COPD	60	250	16.7	2.0	1.56	27.4	17.6	Successb
12	52/F	Double	Emphysema	480	200	12.7	0.5	0.70	7.66	11.0	Successb

^aBAL fluid sampling was performed at the transplanted lung.

^bSuccessful eradication of airway fungal colonization and no breakthrough infection within 3 months post-BAL.

^cVoriconazole-resistant strain but sensitive to amphotericin B, posaconazole, and caspofungin.

^dAbbreviations: M, male; F, female; IPF, idiopathic pulmonary fibrosis; COPD, cronic obstructive pulmonary disease; ILD, interstitial lung disease; PAH, pulmonary arterial hypertension; b.i.d., twice daily; NA, not available.

^eMean ± SD, 12.5 ± 6.3.